Company intelligence / Profile preview

Shandong Sinobioway Biomedicine Co., Ltd.

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~476
Development stage: Other

Overview

Approved products include mouse nerve growth factor (Enjingfu) for nerve injury (since 2006), human interferon α2b (Anfulan injection, Jiefu spray) for viral infections, and hepatitis A/B vaccine (Bellaph); ongoing development in nerve growth factors (Phase 2) and analgesics (Phase 1).

Therapeutic areas: NeurologyInfectious DiseasesRheumatologyOncologyOphthalmology
Modalities: Recombinant proteinGrowth factorsVaccineBiological productsInterferons
Industry: Biotech

Partnerships

Beijing Sinobioway Group collaboration with BioAtla (parent-level)

Beyond the preview

Go deeper on Shandong Sinobioway Biomedicine Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shandong Sinobioway Biomedicine Co., Ltd..

Explore the full profile